Erratum to expanded criteria for active surveillance in prostate cancer: a review of the current data
Erratum

Erratum to expanded criteria for active surveillance in prostate cancer: a review of the current data

Cameron Jones1, Mina M. Fam2, Benjamin J. Davies2

1University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Correspondence to: Cameron Jones. 1100 Liberty Ave., Suite 507, Pittsburgh, PA 15222, USA. Email: ccj8@pitt.edu.

doi: 10.21037/tau.2018.08.05


Erratum to: Transl Androl Urol 2018;7:221-7.


Expanded criteria for active surveillance in prostate cancer: a review of the current data

The article entitled “Expanded criteria for active surveillance in prostate cancer: a review of the current data” (1) published in Vol 7, No 2 of Translational Andrology and Urology included an error in the second sentence of Abstract. In that sentence, “mortality (PCSM)” should be changed to “survival”.

Therefore, the correct sentence should be “Appropriately selected AS patients have a 10-year prostate cancer-specific survival approaching 99%.”

We regret the error and any inconvenience it might have caused.


References

  1. Jones C, Fam MM, Davies BJ. Expanded criteria for active surveillance in prostate cancer: a review of the current data. Transl Androl Urol 2018;7:221-7. [Crossref] [PubMed]
Cite this article as: Jones C, Fam MM, Davies BJ. Erratum to expanded criteria for active surveillance in prostate cancer: a review of the current data. Transl Androl Urol 2018;7(4):764. doi: 10.21037/tau.2018.08.05